FHND5071: a selective RET inhibitor with unique pharmacokinetic profile

被引：1
|
作者：
Zhu, Yongqiang
Wang, Jia
Shang, Minghong
机构：
来源：
CANCER RESEARCH | 2023年 / 83卷 / 08期
关键词：
D O I：
10.1158/1538-7445.AM2023-LB330
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
FHND5071
引用
收藏
页数：2
相关论文
共 50 条
  • [41] Vepafestinib is a pharmacologically advanced RET-selective inhibitor with high CNS penetration and inhibitory activity against RET solvent front mutations
    Miyazaki, Isao
    Odintsov, Igor
    Ishida, Keiji
    Lui, Allan J. W.
    Kato, Masanori
    Suzuki, Tatsuya
    Zhang, Tom
    Wakayama, Kentaro
    Kurth, Renate I.
    Cheng, Ryan
    Fujita, Hidenori
    Delasos, Lukas
    Vojnic, Morana
    Khodos, Inna
    Yamada, Yukari
    Ishizawa, Kota
    Mattar, Marissa S.
    Funabashi, Kaoru
    Chang, Qing
    Ohkubo, Shuichi
    Yano, Wakako
    Terada, Ryuichiro
    Giuliano, Claudio
    Lu, Yue Christine
    Bonifacio, Annalisa
    Kunte, Siddharth
    Davare, Monika A.
    Cheng, Emily H.
    de Stanchina, Elisa
    Lovati, Emanuela
    Iwasawa, Yoshikazu
    Ladanyi, Marc
    Somwar, Romel
    NATURE CANCER, 2023, 4 (09) : 1345 - +
  • [42] Vepafestinib is a pharmacologically advanced RET-selective inhibitor with high CNS penetration and inhibitory activity against RET solvent front mutations
    Isao Miyazaki
    Igor Odintsov
    Keiji Ishida
    Allan J. W. Lui
    Masanori Kato
    Tatsuya Suzuki
    Tom Zhang
    Kentaro Wakayama
    Renate I. Kurth
    Ryan Cheng
    Hidenori Fujita
    Lukas Delasos
    Morana Vojnic
    Inna Khodos
    Yukari Yamada
    Kota Ishizawa
    Marissa S. Mattar
    Kaoru Funabashi
    Qing Chang
    Shuichi Ohkubo
    Wakako Yano
    Ryuichiro Terada
    Claudio Giuliano
    Yue Christine Lu
    Annalisa Bonifacio
    Siddharth Kunte
    Monika A. Davare
    Emily H. Cheng
    Elisa de Stanchina
    Emanuela Lovati
    Yoshikazu Iwasawa
    Marc Ladanyi
    Romel Somwar
    Nature Cancer, 2023, 4 : 1345 - 1361
  • [43] 0623170, a potent URAT1 inhibitor with a favorable pharmacokinetic and toxicity profile
    Yang, Jennifer Xiaoqing
    Yang, Chun
    Bowlin, Steve
    Wilker, Clynn
    Yan, Rongzi
    Miner, Jeff N.
    Hyndman, David
    Ouk, Samedy
    Girardet, Jean-Luc
    Vernier, Jean-Michel
    Quart, Barry
    Yeh, Li-Tain
    DRUG METABOLISM REVIEWS, 2011, 43 : 85 - 86
  • [44] Clinical Pharmacokinetic, Pharmacodynamic and Drug-Interaction Profile of the Integrase Inhibitor Dolutegravir
    Cottrell, Mackenzie L.
    Hadzic, Tanja
    Kashuba, Angela D. M.
    CLINICAL PHARMACOKINETICS, 2013, 52 (11) : 981 - 994
  • [45] Pharmacokinetic Profile of Gilteritinib: A Novel FLT-3 Tyrosine Kinase Inhibitor
    Angela Joubert James
    Catherine C. Smith
    Mark Litzow
    Alexander E. Perl
    Jessica K. Altman
    Dale Shepard
    Takeshi Kadokura
    Kinya Souda
    Melanie Patton
    Zheng Lu
    Chaofeng Liu
    Selina Moy
    Mark J. Levis
    Erkut Bahceci
    Clinical Pharmacokinetics, 2020, 59 : 1273 - 1290
  • [46] Pharmacokinetic and pharmacodynamic profile of the oral α4 integrin inhibitor, CDP323
    Watt, G.
    Shock, A.
    Hales, P.
    Foulkes, R.
    Parton, T.
    Baker, M.
    Sidhu, J.
    MULTIPLE SCLEROSIS, 2009, 15 (09): : S130 - S130
  • [47] Leveraging Atropisomerism to Obtain a Selective Inhibitor of RET Kinase with Secondary Activities toward EGFR Mutants
    Toenjes, Sean T.
    Garcia, Valeria
    Maddox, Sean M.
    Dawson, Gregory A.
    Ortiz, Maria A.
    Piedrafita, F. Javier
    Gustafson, Jeffrey L.
    ACS CHEMICAL BIOLOGY, 2019, 14 (09) : 1930 - 1939
  • [48] Selective inhibition of RET mediated cell proliferation in vitro by the kinase inhibitor SPP86
    Alao, John P.
    Michlikova, Sona
    Diner, Peter
    Grotli, Morten
    Sunnerhagen, Per
    BMC CANCER, 2014, 14
  • [49] Leveraging atropisomerism to obtain a selective inhibitor of RET kinase with secondary activities towards EGFR mutants
    Toenjes, Sean
    Garcia, Valeria
    Maddox, Sean
    Dawson, Gregory
    Ortiz, Maria
    Piedrafita, Javier
    Gustafson, Jeffery
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2019, 258
  • [50] Pharmacokinetic Profile of Gilteritinib: A Novel FLT-3 Tyrosine Kinase Inhibitor
    James, Angela Joubert
    Smith, Catherine C.
    Litzow, Mark
    Perl, Alexander E.
    Altman, Jessica K.
    Shepard, Dale
    Kadokura, Takeshi
    Souda, Kinya
    Patton, Melanie
    Lu, Zheng
    Liu, Chaofeng
    Moy, Selina
    Levis, Mark J.
    Bahceci, Erkut
    CLINICAL PHARMACOKINETICS, 2020, 59 (10) : 1273 - 1290
12345